Name | [1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]- |
---|---|
Synonyms |
4'-[(1R,2S)-2-Aminocyclopropyl]-3-biphenylol
[1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]- 4'-((1R,2S)-2-Aminocyclopropyl)biphenyl-3-ol OG-L002 |
Description | OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IEgenes[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.02 μM (LSD1), 1.38 μM (MAO-A), 0.72 μM (MAO-B), HSV IE[1] |
In Vitro | OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC50 (IC50: ~10 µM in HeLa cells; IC50: ~3 µM in HFF cells) relative to the control MAOI TCP (IC50: ~1 mM)[1]. |
In Vivo | OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection[1]. Animal Model: 4-week-old BALB/c female mice[1] Dosage: 6, 20, 40 mg/kg Administration: Intraperitoneal; daily; for 7 days Result: Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 416.7±45.0 °C at 760 mmHg |
Molecular Formula | C15H15NO |
Molecular Weight | 225.286 |
Flash Point | 205.8±28.7 °C |
Exact Mass | 225.115356 |
PSA | 46.25000 |
LogP | 2.27 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.644 |
Storage condition | -20℃ |
Water Solubility | Very slightly soluble (0.22 g/L) (25 ºC) |